Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	418910	SPIKEVAX XBB.1.5 (andusomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial - single-dose

ARTG entry for	Medicine Registered
Sponsor	Moderna Australia Pty Ltd
Postal Address	L49, 101 Collins St, Melbourne, VIC, 3000 Australia
ARTG Start Date	10/10/2023
Product Category	Medicine
Status	Active
Approval Area	Drug Safety Evaluation Branch

Medicine under additional monitoring

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 February 1992, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 February 1992, other than condition No. 11.

Except where the sponsor has been contracted by an overseas partry to manufacturer the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods, and upon the request of the Head, Office of Prescription Medicines Authorisation Branch, Therapeutic Goods Administration, shall produce such evidence to this officer.

The conditions applying to these goods when they are exported from Australia are given below:

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

The therapeutic goods grouped in this registration/listing as export only goods under the following names are included in the Australian Register of Therapeutic Goods and may not be supplied in Australia. Export Name(s) to be added:

Products

1 . SPIKEVAX XBB.1.5 (andusomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial - single-dose

Product Type	Single Medicine Product	**Effective Date**	8/04/2024

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

SPIKEVAX XBB.1.5 (andusomeran) COVID-19 Vaccine is indicated for: Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.

Warnings

See Product Information and Consumer Medicine Information for this product

Additional Product information

This product is included in the Black Triangle Scheme

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Vial	Glass Type I Clear	9 Months	Store between minus 50 - minus 15 degrees Celsius	Neither child resistant closure nor restricted flow insert	Store in Original Container Protect from Light

Pack Size/Poison information

Pack Size	Poison Schedule
10 x 0.5 mL vials	(S4) Prescription Only Medicine

Components

1 . SPIKEVAX XBB.1.5 (andusomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial - single-dose

Dosage Form	Injection, suspension
Route of Administration	Intramuscular
Visual Identification	White to off-white frozen suspension

Active Ingredients

andusomeran	**.1 mg/mL**

Other Ingredients (Excipients)

1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000
cholesterol
distearoylphosphatidylcholine
glacial acetic acid
heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate
sodium acetate trihydrate
sucrose
trometamol hydrochloride
trometamol
water for injections

Public Summary